129 related articles for article (PubMed ID: 16231313)
21. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
22. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.
Schwartz LH; Seymour L; Litière S; Ford R; Gwyther S; Mandrekar S; Shankar L; Bogaerts J; Chen A; Dancey J; Hayes W; Hodi FS; Hoekstra OS; Huang EP; Lin N; Liu Y; Therasse P; Wolchok JD; de Vries E
Eur J Cancer; 2016 Jul; 62():138-45. PubMed ID: 27237360
[TBL] [Abstract][Full Text] [Related]
23. The minimum number of target lesions that need to be measured to be representative of the total number of target lesions (according to RECIST).
Darkeh MH; Suzuki C; Torkzad MR
Br J Radiol; 2009 Aug; 82(980):681-6. PubMed ID: 19366735
[TBL] [Abstract][Full Text] [Related]
24. Response criteria in oncologic imaging: review of traditional and new criteria.
Tirkes T; Hollar MA; Tann M; Kohli MD; Akisik F; Sandrasegaran K
Radiographics; 2013; 33(5):1323-41. PubMed ID: 24025927
[TBL] [Abstract][Full Text] [Related]
25. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors.
Aras M; Erdil TY; Dane F; Gungor S; Ones T; Dede F; Inanir S; Turoglu HT
Nucl Med Commun; 2016 Jan; 37(1):9-15. PubMed ID: 26440568
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
Forner A; Ayuso C; Varela M; Rimola J; Hessheimer AJ; de Lope CR; Reig M; Bianchi L; Llovet JM; Bruix J
Cancer; 2009 Feb; 115(3):616-23. PubMed ID: 19117042
[TBL] [Abstract][Full Text] [Related]
27. Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation.
Mansour N; Heinrich K; Zhang D; Winkelmann M; Ingenerf M; Gold L; Klambauer K; Rudelius M; Klauschen F; von Bergwelt-Baildon M; Ricke J; Heinemann V; Westphalen CB; Kunz WG
Cancer Imaging; 2024 Jun; 24(1):70. PubMed ID: 38849902
[TBL] [Abstract][Full Text] [Related]
28. [A summary report of response evaluation criteria in solid tumors (RECIST criteria)].
Kusaba H; Saijo N
Gan To Kagaku Ryoho; 2000 Jan; 27(1):1-5. PubMed ID: 10660728
[TBL] [Abstract][Full Text] [Related]
29. RECIST - learning from the past to build the future.
Litière S; Collette S; de Vries EG; Seymour L; Bogaerts J
Nat Rev Clin Oncol; 2017 Mar; 14(3):187-192. PubMed ID: 27995946
[TBL] [Abstract][Full Text] [Related]
30. Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer.
Kimura M; Tominaga T
Breast Cancer; 2002; 9(2):153-9. PubMed ID: 12016395
[TBL] [Abstract][Full Text] [Related]
31. Radiologic measurements of tumor response to treatment: practical approaches and limitations.
Suzuki C; Jacobsson H; Hatschek T; Torkzad MR; Bodén K; Eriksson-Alm Y; Berg E; Fujii H; Kubo A; Blomqvist L
Radiographics; 2008; 28(2):329-44. PubMed ID: 18349443
[TBL] [Abstract][Full Text] [Related]
32. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Sun JM; Ahn MJ; Park MJ; Yi JH; Kim TS; Chung MJ; Park YH; Ahn JS; Park K
Lung Cancer; 2010 Jul; 69(1):105-9. PubMed ID: 19959251
[TBL] [Abstract][Full Text] [Related]
33. Reviewing RECIST in the Era of Prolonged and Targeted Therapy.
Morgan RL; Camidge DR
J Thorac Oncol; 2018 Feb; 13(2):154-164. PubMed ID: 29113950
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the response to therapy of neoplastic lesions.
Bellomi M; Preda L
Radiol Med; 2004; 107(5-6):450-8. PubMed ID: 15195007
[TBL] [Abstract][Full Text] [Related]
35. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
Liu Q; Li A; Sun S; Luo R; Chen F
J BUON; 2014; 19(2):398-405. PubMed ID: 24965398
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of pediatric cancer survivors: education, surveillance, and screening.
Landier W; Wallace WH; Hudson MM
Pediatr Blood Cancer; 2006 Feb; 46(2):149-58. PubMed ID: 16369924
[TBL] [Abstract][Full Text] [Related]
37. [CT evaluation of response to chemotherapy and/or radiotherapy in primary lung cancer: comparison of response evaluation criteria in solid tumors (RECIST) and the WHO criteria, and comparison of both methods with the histological evaluation].
Konishi K; Kuriyama K; Chino S; Isohashi K; Murata M; Tsuda K; Mitani T; Maeda M; Kadota T; Arisawa J
Nihon Igaku Hoshasen Gakkai Zasshi; 2004 Jan; 64(1):41-5. PubMed ID: 14994510
[TBL] [Abstract][Full Text] [Related]
38. Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond.
Nishino M
Am Soc Clin Oncol Educ Book; 2018 May; 38():1019-1029. PubMed ID: 30231378
[TBL] [Abstract][Full Text] [Related]
39. CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure.
Zacharia TT; Saini S; Halpern EF; Sumner JE
AJR Am J Roentgenol; 2006 Apr; 186(4):1067-70. PubMed ID: 16554580
[TBL] [Abstract][Full Text] [Related]
40. RECIST 1.1-Update and clarification: From the RECIST committee.
Schwartz LH; Litière S; de Vries E; Ford R; Gwyther S; Mandrekar S; Shankar L; Bogaerts J; Chen A; Dancey J; Hayes W; Hodi FS; Hoekstra OS; Huang EP; Lin N; Liu Y; Therasse P; Wolchok JD; Seymour L
Eur J Cancer; 2016 Jul; 62():132-7. PubMed ID: 27189322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
